Editorial Board About Us

Erectile dysfunction

All articles from this key word are listed below.

Volume 10, Number 1 Review Articles

Impact of Phosphodiesterase Type 5 Inhibitors on Endothelial Function

Treatment Update

Patrick E Teloken John P Mulhall

It is now known that endothelial health is essential for normal erectile function, and changes in endothelial integrity or function may lead to erectile dysfunction (ED). Because phosphodiesterase type 5 (PDE-5) inhibitors have been shown to improve endothelial function, many investigators have questioned whether PDE-5 inhibition will lead to improvement in erectile function. Data from the studies reviewed in this article show that therapy with PDE-5 inhibitors results in improvement in flow-mediated dilation, nocturnal penile tumescence and rigidity, and carotid artery intima-media thickness as well as higher scores on the Sexual Health Inventory for Men, International Index of Erectile Function, Erection Function Domain, and other instruments. Further research is needed to determine whether long-term PDE-5 inhibition can reverse ED and whether use of these agents will decrease cardiovascular morbidity in high-risk populations. [Rev Urol. 2008;10(1):26-30]

Erectile dysfunction Tadalafil Sildenafil Endothelial function Phosphodiesterase type 5inhibitors

Volume 11, Number 4 Meeting Reviews

Best of the 2008 Sexual Medicine Society of North America

Highlights From the Sexual Medicine Society of North America, October 16-19, 2008, Toronto, Ontario, Canada[Rev Urol. 2009;11(4):213-215 doi: 10.3909/riu0466]© 2009 MedReviews®, LLC

Erectile dysfunction Gene splicing PDE5 inhibitors Sexual medicine

Volume 11, Number 3 Meeting Reviews

New Findings in Prostate Cancer

Franklin E Kuehhas Bob Djavan

Highlights From the 24th Annual Congress of the European Association of Urology,March 17–21, 2009, Stockholm, Sweden[Rev Urol. 2009;11(3):169-172 doi:10.3909/riu0455]

Prostate cancer Erectile dysfunction Urinary incontinence Pelvic lymph node dissection Staging European Randomized Study of Screening for Prostate Cancer (ERSPC)

Volume 12, Number 1 Case Review

Diagnostic and Therapeutic Options for the Management of Ischemic and Nonischemic Priapism

Case Review

Jeffrey Bassett Jacob Rajfer

Priapism is defined as persistent penile erection continuing beyond, or unrelated to, sexual stimulation. Proper diagnosis encompasses at least 2 very different pathophysiologic processes. Ischemic priapism (“low flow”) is a disorder of venous outflow and/or stasis. Nonischemic priapism (“high flow”) is a disorder of arterial flow. We present 2 cases that review each condition. The first case highlights a 32-year-old man with a medical history of sickle cell disease who presented to the emergency department complaining of a persistent, painful erection that had continued for 18 hours. The second case describes a 24-year-old man with no significant medical history who sustained trauma to his pelvis while skateboarding. Although the initial evaluation of both types of priapism is similar, pathophysiology and resulting interventions differ for each, underscoring the importance of proper diagnosis.[Rev Urol. 2010;12(1):56-63 doi: 10.3909/riu0457]

Erectile dysfunction Ischemic priapism Nonischemic priapism Intracorporeal pressure Cavernosal hypoxia Phosphodiesterase type 5 Distal shunts

Volume 13, Number 1 Review Articles

Postprostatectomy Erectile Dysfunction: The Role of Penile Rehabilitation

Management Update

Michael J Kennelly Culley C Carson Brian P DeFade

"Radical prostatectomy has become the gold standard for the treatment of prostate cancer in patients who have a longer than 10-year life expectancy. Surgical treatment has led to severe quality-of-life issues in these patients, especially urinary incontinence and erectile dysfunction (ED). This article reviews the etiology and pathophysiology of postprostatectomy ED, and current management strategies for these patients. [Rev Urol. 2011;13(1):6-13 doi: 10.3909/riu0501]"

Erectile dysfunction Penile rehabilitation Prostatectomy

Volume 14, Number 3 Review Articles

Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia

Treatment Update

Richard K Lee Dean S Elterman Steven A Kaplan Alexis E Te Bilal Chughtai

Many aging men will experience both erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), resulting in lower urinary tract symptoms (LUTS). Basic and clinical evidence suggests common pathogenic mechanisms underlying both LUTS and ED. Decreases in the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway with age result in decreased levels of intracellular cGMP and calcium, leading to diminished smooth muscle relaxation of the bladder and prostate and worsening LUTS. Phosphodiesterase type 5 inhibitors as monotherapy in combination with a-blockers have shown efficacy in treating both LUTS and ED. Tadalafil has recently been approved by the US Food and Drug Administration for the treatment of LUTS secondary to BPH, with or without concomitant ED. [Rev Urol. 2012;14(3/4):79-86 doi: 10.3909/riu0559] © 2013 MedReviews®, LLC

Benign prostatic hyperplasia Lower urinary tract symptoms Erectile dysfunction Phosphodiesterase inhibitors Tadalafil Sildenafil Vardenafil

Volume 15, Number 2 Review Articles

The Use of Vacuum Erection Devices in Erectile Dysfunction After Radical Prostatectomy

Management Update

James Adshead Kimberley Hoyland Nikhil Vasdev

The risk of postoperative erectile dysfunction (ED) following radical prostatectomy (RP) is reported to be between 14% and 89%. With an increase in the detection of prostate cancer in younger men, there is a greater emphasis on the appropriate management of ED following RP. A number of options are available to manage ED after RP, including phosphodiesterase-5 inhibitors, intracorporeal injections, intraurethral alprostadil, and vacuum erection devices (VEDs). Penile rehabilitation programs are increasingly used to facilitate the return of natural postoperative erections; the VED is an ideal therapy given that it increases blood flow and oxygenation to the corpora to reverse the changes that result in ED after RP. [Rev Urol. 2013;15(2):67-71 doi: 10.3909/riu0574] © 2013 MedReviews®, LLC

Radical prostatectomy Erectile dysfunction Penile rehabilitation Vacuum erection device

Volume 15, Number 2 Meeting Reviews

Best of the 2013 AUA Annual Meeting

Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA

Prostate cancer PSA screening Nephrolithiasis Overactive bladder PCA3 Interstitial cystitis Prostate biopsy Transrectal ultrasound Erectile dysfunction Cystectomy Chronic pelvic pain syndrome Shock wave lithotripsy Prostate markers

Volume 16, Number 3 Review Articles

Management of Erectile Dysfunction in the Hypogonadal Man: A Case-Based Review

Management Review

Larry I Lipshultz Jason R Kovac Nathan A Wilken Ranjith Ramasamy Jason M Scovell

Erectile dysfunction (ED) has emerged as an important marker of cardiovascular and overall health, independent of other known conventional risk factors. ED often precedes coronary artery disease in half of affected subjects, and could indicate the presence of cardiovascular pathology. The pathophysiology and role of androgens in sexual function are described, along with the relevant literature on the effects of aging in erectile and gonadal function. The concept of testosterone supplementation (TST) in men with ED is reviewed. The authors utilize clinical vignettes to discuss the appropriate management of two clinical cases of men at different life stages who have ED in the setting of hypogonadism and propose a treatment algorithm. In patients of all ages, proper identification of the underlying pathophysiology of decreased libido and erectile function is paramount in choosing between the use of TST, phosphodiesterase type 5 inhibitors, or both, in the management of these disorders. [Rev Urol. 2014;16(3):105-109 doi: 10.3909/riu0623] © 2014 MedReviews®, LLC

Hypogonadism Erectile dysfunction Testosterone supplementation Phosphodiesterase

Volume 17, Number 4 Book Reviews

Smoking: Its Impact on Urologic Health

Management Update

David Mobley Neil Baum

Tobacco use remains the single largest preventable cause of disease and premature death in the United States, and smoking is a leading cause of cancer and death from cancer. There is also evidence that smoking is associated with several urologic diseases. Urologists have a unique opportunity to help our patients lead healthy lifestyles, which includes ending their dependence on nicotine and tobacco. This article points out the various urologic conditions associated with smoking and tobacco use with the intention of providing physicians and patients with knowledge and education regarding this connection. [Rev Urol. 2015;17(4):220-225 doi: 10.3909/riu0684] © 2016 MedReviews®, LLC

Prostate cancer Bladder cancer Kidney cancer Interstitial cystitis Smoking Erectile dysfunction